ATLANTA, GA – – (ACCESSWIRE – June 15, 2022) – – Holzer & Holzer, LLC is investigating whether Outset Medical, Inc. (“Outset Medical” or the “Company”) (NASDAQ: OM) complied with federal securities laws. On June 13, 2022, Outset Medical announced it “implemented a shipment hold on the distribution of its Tablo Hemodialysis System…pending the Food and Drug Administration’s (FDA) review and clearance of a 510(k) the company submitted” for changes made to the device and further announced it was suspending its prior guidance. Following this news, the Company’s stock price dropped. If you purchased Outset Medical stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at email@example.com or Joshua Karr, Esq. at firstname.lastname@example.org, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com to discuss your legal rights.